Board Refresh, page-225

The Sleep Apnea App is becoming increasingly important for the company. Thank the gods we have this second string for our bow.
Coviu will go ahead. It will give RAP some revenue and Covid19 cough data.
A few European telehealth companies will begin to use Resappdx,
By the time TK meets the FDA there will be a great track record of accurate diagnosis at Coviu which may sway them,
Joondalup will start using RAP in the Emergency Department where clinical trials were run.
Just Fox trying think positively in all the gloom.
PS. Been on a few company boards. Agree with Taurean. However appreciate the effort to lynch somebody. More interested in who joins the board rather than who goes.
Fox